10-Q: Milestone Scientific Reports First Quarter 2024 Results, Revenue Declines Amid Strategic Shift

Milestone Scientific's first quarter 2024 results show a decrease in revenue compared to the same period last year, alongside a net loss, as the company continues its transition to a commercially focused medical device company.

Summary

• Milestone Scientific reported a net loss of $1.44 million for the first quarter of 2024, compared to a net loss of $1.31 million for the same period in 2023.
• The company's total revenue decreased to $2.25 million in Q1 2024 from $2.6 million in Q1 2023, primarily due to a decline in dental product sales.
• Gross profit for the quarter was $1.68 million, down from $1.89 million in the prior year.
• Operating expenses totaled $3.14 million, slightly down from $3.23 million in the first quarter of 2023.
• The company's cash and cash equivalents, along with marketable securities, totaled approximately $5.0 million as of March 31, 2024.
• Milestone Scientific is actively pursuing positive cash flow through increased dental and medical device sales, and reduced operating expenses.
• The company sold $2.0 million worth of Net Operating Losses (NOLs) in April 2024 through the New Jersey Technology Business Tax Certificate Transfer Program.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with declining revenue and increased losses, but also highlights some positive developments such as e-commerce growth and cost control efforts. The company's reliance on future capital raises and the risks associated with its business model temper the overall sentiment.

Positives

• E-commerce sales increased to 53% of net product sales, indicating a successful shift in sales strategy.
• Operating expenses saw a slight decrease, showing some cost control.
• The company successfully sold $2.0 million worth of NOLs, improving its financial position.
• Milestone Scientific is actively pursuing positive cash flow through increased sales and reduced expenses.

Negatives

• The company experienced a net loss of $1.44 million, which is worse than the $1.31 million loss in the same period last year.
• Total revenue decreased by approximately $349,000 compared to the first quarter of 2023.
• Gross profit decreased by approximately $213,000 compared to the first quarter of 2023.
• International revenue decreased by $274,000 compared to the first quarter of 2023.

Risks

• The company has incurred total losses of $124.8 million since inception and expects to continue to incur operating losses.
• Milestone Scientific relies on third-party manufacturers, and any disruption could negatively impact production and sales.
• The company's continued operations depend on its ability to raise additional capital.
• The company faces risks related to international sales and operations, including in China.
• Changes in distribution arrangements could interrupt marketing efforts and require building new marketing channels.
• The company is exposed to risks of shortages or delays in obtaining chips and other components for manufacturing.

Future Outlook

Milestone Scientific is focused on expanding its global footprint, increasing sales of its dental and medical devices, and reducing operating expenses to achieve profitability. The company is also working on the development of the next generation STA Single Tooth Anesthesia System.

Management Comments

• Milestone Scientific remains focused on advancing efforts to achieve the following three primary objectives: Establishing Milestones DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time, objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications; Following obtaining successful FDA clearance of our first medical device, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company; and Expanding our global footprint of our CompuFlo Epidural and CathCheck System by utilizing a targeted field sales force and partnering with distribution companies worldwide.
• We believe our technologies are proven and well established.
• Our computer-controlled injection devices make injections precise, efficient, and virtually painless.

Industry Context

The company's focus on computer-controlled injection technology aligns with the broader trend in the medical and dental industries towards more precise, efficient, and patient-friendly procedures. The company's expansion into the medical market with its CompuFlo Epidural System is a strategic move to diversify its revenue streams and capitalize on the growing demand for advanced pain management solutions.

Comparison to Industry Standards

• Milestone Scientific's revenue decline contrasts with some medical device companies that have shown growth in the same period, such as Stryker and Medtronic, which have reported positive revenue growth in their recent quarterly results.
• The company's net loss is also a concern, as many established medical device companies are profitable, such as Johnson & Johnson and Abbott.
• However, Milestone Scientific is still in a growth phase and is investing in new product development and market expansion, which may explain the current losses.
• Compared to smaller, emerging medical device companies, Milestone Scientific's financial performance is mixed, with some peers showing faster revenue growth but also incurring losses.
• The company's reliance on third-party manufacturers is a common practice in the industry, but it also introduces risks that need to be managed effectively.

Related Party Transactions

• Milestone Scientific has a supply agreement with United Systems, a related party, for the manufacturing of handpieces.
• The Director of Clinical Affairs receives royalty and consulting fees from the company.
• Leonard Osser, a director, has a Royalty Sharing Agreement and receives compensation under Employment and Consulting Agreements.
• Dr. D. Demesmin, a board member, has a related party transaction with the company through the University Pain Medicine Center (STEMMEE).

Stakeholder Impact

• Shareholders may be concerned about the company's continued losses and reliance on future capital raises.
• Employees may be affected by potential cost-cutting measures.
• Customers may benefit from the company's innovative products and technologies.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to focus on expanding its global footprint.
• Milestone Scientific will continue to increase sales of its dental and medical devices.
• The company will continue to reduce operating expenses to achieve profitability.
• Milestone Scientific will continue the development of the next generation STA Single Tooth Anesthesia System.

Key Dates

Keywords

Milestone Scientific, medical devices, dental, anesthesia, CompuFlo, STA System, revenue, net loss, financial results, operating expenses, e-commerce, NOLs